Sheet 1					Т			
EORM PTO 1449 (modified)						y Docket -	P6790	00US1 ·
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE					Application No 10/513,962			
LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)					Applicant - Forssmann, et al.			
					Filing D	ate –	ary 8, 2005	
RADENA			U.S. PATENT D	OCUMENTS			. 	· · · · · · · · · · · · · · · · · · ·
Examiner [†]	Ref. #		ļ		Date	Pa	tentee/Applicant	
				<u> </u>				
-						·		·
M		· · · · · · · · · · · · · · · · · · ·						
								
			FOREIGN PATENT	T DOCUMENT	TC			
		Country	. Document No.	Translation		Date		Patentee
/S.G./	-	EP	1 167 527	Translation	Abstract	01/02/02		Patentee
		<u> </u>	1 107 327			01/02/02		
				0				
					0			·
		-					-	
				<u> </u>	0			
				0	0			
			NON-PATENT D	OCUMENTS		·		
Examiner	Ref. #	Author (in CAPITAL LETTERS), Title, Book or Periodical, Volume, Date, Pages)						
/S.G./		Detheux, M., et al., "Natural proteolytic processing of hemofiltrate CC chemokine 1 generates a potent CC chemokine receptor (CCR)1 and CCR5 agonist with anti-HIV properties," The Journal of Experimental Medicine, vol. 192, no. 10, November 20, 2000, pgs. 1501-1508, [XP002241991].						
/S.G./		Muench, J., et al., "Hemofiltrate CC chemokine 1(9-74) causes effective internalization of CCR5 and is a potent inhibitor of R5-tropic human immunodeficiency virus type 1 strains in primary T cells and macrophages," Antimicrobial Agents and Chemotherapy, vol. 46, no. 4, April 2002, pgs. 982-990, [XP002241992].						
/S.G./		Teran, L. M., "CCL Chemokines and asthma," Immunology Today, vol. 21, no. 5, May 2000, pgs. 235-242, [XP004198513].						
Examiner Si	gnature	/Satyaı	narayan Gudibande/					Date Considered

[†]Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.